Effect of age on drug metabolism in women with breast cancer

Expert Opinion on Drug Metabolism and Toxicology

Volumn 11, Issue 5, 2015, Pages 757-766

  Singh, Jasmeet C ^a   Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CYP450; Elderly; Geriatrics; Pharmacodynamics; Pharmacokinetics; Polypharmacy; Renal insufficiency

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROPYRIMIDINE; FLUOROURACIL; METHOTREXATE; NAVELBINE; TAMOXIFEN; TAXANE DERIVATIVE;

AGING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CARDIOTOXICITY; COMORBIDITY; DRUG METABOLISM; FUNCTIONAL STATUS; HUMAN; MOLECULARLY TARGETED THERAPY; MULTIPLE ORGAN FAILURE; NEUROPATHY; POLYPHARMACY; REVIEW; AGE; BREAST NEOPLASMS; DRUG INTERACTION; EVIDENCE BASED MEDICINE; FEMALE; METASTASIS; PATHOLOGY;

AGE FACTORS; AGING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG INTERACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; POLYPHARMACY;

EID: 84928881479     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2015.1037277     Document Type: Review

References (99)

1. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7
2. Lichtman SM, Budman DR. AdjuVant therapy for node-negative breast cancer. N Engl J Med 1989;321:469-73; letter
3. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30:2036-8
4. Carlson RW, Moench S, Hurria A, et al. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw 2008;6(Suppl 4): S1-S25; quiz S26-S27
5. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011;29:3457-65
6. de Glas NA, Van de Water W, Engelhardt EG, et al. Validity of AdjuVant! Online program in older patients with breast cancer: a populationbased study. Lancet Oncol 2014;15:722-9
7. Hurria A, Lichtman SM, Gardes J, et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 2007;55:1604-8
8. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 2005;104:1998-2005
9. Bouchardy C, Rapiti E, Blagojevic S, et al. Older female cancer patients: importance, causes, and consequences of undertreatment. J Clin Oncol 2007;25:1858-69
10. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-6
11. Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol 2012;23(Suppl 6):vi52-5
12. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003;21:2268-75
13. Leonard R, Ballinger R, Cameron D, et al. AdjuVant chemotherapy in older women (ACTION) study-what did we learn from the pilot phase Br J Cancer 2011;105:1260-6
14. Muss HB, Woolf S, Berry D, et al. AdjuVant chemotherapy in older and younger women with lymph nodepositive breast cancer. JAMA 2005;293:1073-81
15. Van Leeuwen BL, Rosenkranz KM, Feng LL, et al. The effect of undertreatment of breast cancer in women 80 years of age and older. Crit Rev Oncol Hematol 2011;79:315-20
16. Early Breast Cancer Trialists' Collaborative G. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 2012;379:432-44
17. Muss HB, Berry DA, Cirrincione CT, et al. AdjuVant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009;360:2055-65
18. Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuVant chemotherapy in older women with breast cancer. J Clin Oncol 2006;24:2750-6
19. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuVant chemotherapy in women with breast cancer. Cancer Invest 2000;18:521-9
20. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998;16:1811-19
21. Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000;18:2780-7
22. Venook AP, Enders Klein C, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003;14:1783-90
23. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007;25:1832-43
24. Lichtman SM, Skirvin JA, Vemulapalli S. Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 2003;46:101-14
25. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med 1997;13:169-83
26. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med 1990;6:257-67
27. Neugut AI, Subar M, Wilde ET, et al. Association between prescription copayment amount and compliance with adjuVant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 2011;29:2534-42
28. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuVant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6
29. Ruddy KJ, Pitcher BN, Archer LE, et al. Persistence, adherence, and toxicity with oral CMF in older women with earlystage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 2012;23:3075-81
30. Partridge AH, Archer L, Kornblith AB, et al. Adherence and persistence with oral adjuVant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010;28:2418-22
31. Maggiore RJ, Dale W, Gross CP, et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapyrelated toxicity and hospitalization during treatment. J Am Geriatr Soc 2014;62:1505-12
32. Popa M, Wallace K, Brunello A, Extermann M. The impact of polypharmacy on toxicity from chemotherapy in elderly patients: Focus on cytochrome P-450 inhibition and protein binding effects. ASCO Meeting Abstr 2008;26:9505
33. Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf 2007;6:695-704
34. Lichtman SM, Boparai MK. Anticancer drug therapy in the older cancer patient: pharmacology and polypharmacy. Curr Treat Options Oncol 2008;9:191-203
35. American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31
36. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol 2004;15:291-5
37. Launay-Vacher V, Chatelut E, Lichtman S, et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007;18:1314-21
38. Lichtman SM, Wildiers H, Launay-Vacher V, et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 2007;43:14-34
39. Launay-Vacher V, Gligorov J, Le Tourneau C, et al. Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat 2010;124:745-53
40. Shah RR. Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol 2004;58:452-69
41. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005;11:449-60
42. Baker SD, Van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res 2004;10:8341-50
43. Lichtman SM, Hurria A, Cirrincione CT, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2012;23:632-8
44. Hurria A, Lichtman SM. Clinical pharmacology of cancer therapies in older adults. Br J Cancer 2008;98:517-22
45. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. Oncology (Williston Park) 2009;23:227-34
46. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9:23-33
47. Maggiore RJ, Gross CP, Togawa K, et al. Use of complementary medications among older adults with cancer. Cancer 2012;118:4815-23
48. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herbdrug combinations used by cancer patients. Integr Cancer Ther 2009;8:29-36
49. Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-503
50. Hamaker ME, Seynaeve C, Wymenga AN, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists' group. Breast 2014;23:81-7
51. Widmer N, Bardin C, Chatelut E, et al. Review of therapeutic drug monitoring of anticancer drugs part two-targeted therapies. Eur J Cancer 2014;50:2020-36
52. Doki K, Homma M, Kuga K, et al. Effects of CYP2D6 genotypes on agerelated change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 2009;68:89-96
53. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry 2009;70:1688-97
54. Henry NL, Stearns V, Flockhart DA, et al. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am J Psychiatry 2008;165:1251-5
55. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002;95:2006-16
56. Garcia-Giralt N, Rodriguez-Sanz M, Prieto-Alhambra D, et al. Genetic determinants of aromatase inhibitorrelated arthralgia: the B-ABLE cohort study. Breast Cancer Res Treat 2013;140:385-95
57. Robert J, Gianni L. Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 1993;17:219-52
58. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-79
59. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003;51:395-402
60. Wade JR, Kelman AW, Kerr DJ, et al. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol 1992;29:391-5
61. Sandstrom M, Lindman H, Nygren P, et al. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicincyclophosphamide regimen in breast cancer patients. Cancer Chemother Pharmacol 2006;58:143-56
62. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival adVantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuVant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuVant study group 08 trial. J Clin Oncol 2004;22:4622-30
63. Crivellari D, Gray KP, Dellapasqua S, et al. AdjuVant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast 2013;22:130-7
64. Basso U, Roma A, Brunello A, et al. Bi-weekly liposomal doxorubicin for adVanced breast cancer in elderly women (‡ 70 years). J Geriatr Oncol 2013;4:340-5
65. Falandry C, Brain E, Bonnefoy M, et al. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. Eur J Cancer 2013;49:2806-14
66. Sparreboom A, Verweij J. Paclitaxel pharmacokinetics, threshold models, and dosing strategies. J Clin Oncol 2003;21:2803-4; author reply 05-6
67. Lichtman SM, Hurria A, Cirrincione CT, et al. Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 2011
68. Smorenburg CH, ten Tije AJ, Verweij J, et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer 2003;39:196-202
69. Hurria A, Blanchard MS, Synold TW, et al. Age-related changes in nanoparticle albumin-bound Paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist 2015;20:37-44
70. Aapro M, Tjulandin S, Bhar P, Gradishar W. Weekly nab-paclitaxel is safe and effective in >/=65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast 2011;20:468-74
71. Pivot X, Schneeweiss A, Verma S, et al. Efficacy and safety of bevacizumab in combination with docetaxel for the firstline treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. Eur J Cancer 2011;47:2387-95
72. Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006;12:6100-5
73. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuVant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol 2000;18:1412-22
74. Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel vs CMF as adjuVant chemotherapy for older women with early breast cancer: final results of the randomised phase 3 ELDA trial. Ann Oncol 2015;26(4):675-82
75. Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol 1999;44:453-60
76. Daher Abdi Z, Lavau-Denes S, Premaud A, et al. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. Cancer Chemother Pharmacol 2014;73:1285-93
77. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75
78. Feliu J, Escudero P, Llosa F, et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 2005;23:3104-11
79. Hu W, Shi J, Sheng Y, et al. Clinical study of adjuVant capecitabine monotherapy in Chinese elderly patients (aged 55-70) with stage IIa breast cancer. Onkologie 2010;33:433-6
80. Wildiers H, Highley MS, de Bruijn EA, Van Oosterom AT. Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet 2003;42:1213-42
81. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17
82. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuVant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7
83. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91
84. Folprecht G, Cunningham D, Ross P, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004;15:1330-8
85. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer 1997;33:301-3
86. Gauvin A, Pinguet F, Culine S, et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with adVanced metastatic cancer. Clin Cancer Res 2000;6:2690-5
87. Wong M, Balleine RL, Blair EY, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006;24:2448-55
88. Baweja M, Suman VJ, Fitch TR, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > or = 65 years of age: an NCCTG study. Ann Oncol 2006;17:623-9
89. Rossi A, Gridelli C, Gebbia V, et al. Single agent vinorelbine as first-line chemotherapy in elderly patients with adVanced breast cancer. Anticancer Res 2003;23:1657-64
90. Kelly CM, Power DG, Lichtman SM. Targeted therapy in older patients with solid tumors. J Clin Oncol 2014;32:2635-46
91. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92
92. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-16
93. Chavez-MacGregor M, Zhang N, Buchholz TA, et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31:4222-8
94. Thomas-Schoemann A, Blanchet B, Bardin C, et al. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 2014;89:179-96
95. Pritchard KI, Burris HA III, Ito Y, et al. Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013;13:421-32; e8
96. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19
97. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive adVanced breast cancer. N Engl J Med 2012;367:1783-91
98. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive adVanced breast cancer. N Engl J Med 2006;355:2733-43
99. Crown JP, Burris HA III, Boyle F, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;112:317-25